Insmed Incorporated (NASDAQ:INSM) saw its shares rise 6.6% on Monday following the release of topline results from the Phase 3b ENCORE clinical trial evaluating ARIKAYCE.
The ENCORE study reached its primary endpoint and met all multiplicity-controlled secondary culture conversion endpoints, showing statistically significant improvement in respiratory symptom scores and culture conversion rates for patients treated with ARIKAYCE plus multidrug therapy versus those receiving placebo plus multidrug therapy.
Specifically, the ARIKAYCE arm produced a 3.11-point improvement in respiratory symptom score at month 13 compared with placebo plus multidrug therapy, with a p-value of 0.0299. In terms of microbiologic outcomes, culture conversion by month 6 occurred in 87.8% of patients in the ARIKAYCE arm versus 57.0% in the placebo arm, a 30.8 percentage-point difference. Durable culture conversion at month 15 was 76.2% in the ARIKAYCE group compared with 47.6% in the placebo group.
The trial population consisted of patients experiencing a new occurrence of Mycobacterium avium complex lung infection who had not previously received antibiotics, and the comparison contrasted ARIKAYCE plus multidrug therapy against placebo plus multidrug therapy.
Insmed reported that the safety profile observed in ENCORE was consistent with the known safety profile of ARIKAYCE and that no new safety signals were identified. Treatment-emergent adverse events occurring at higher rates in the ARIKAYCE arm included dysphonia at 58.7%, cough at 32.9%, and fatigue at 17.4%. Treatment discontinuation occurred in 18.3% of patients receiving ARIKAYCE compared with 11.8% in the comparator arm.
Following the positive topline readout, Insmed outlined regulatory plans tied to the data. The company intends to file a supplemental new drug application with the U.S. Food and Drug Administration in the second half of 2026 to support potential label expansion and to pursue traditional approval for the existing refractory indication. Insmed also plans to submit the ENCORE data to Japan's Pharmaceuticals and Medical Devices Agency during the same timeframe. The company noted that these results complete the study intended to satisfy the FDA post-marketing requirement for ARIKAYCE.
Context and implications
The ENCORE topline results present both clinical and regulatory developments for ARIKAYCE. The statistically significant symptom improvement and higher culture conversion rates provide the efficacy data Insmed will use in planned regulatory actions. The safety findings were consistent with prior experience but did include higher rates of certain adverse events and a higher discontinuation rate in the active arm.
Investors reacted to the release with a share-price uptick on Monday. Insmed's regulatory timeline centers on filings in the second half of 2026 in both the United States and Japan, and the company positions this dataset as the completion of the FDA post-marketing requirement for the product.